Restasis 0.05% Ophthalmic Emulsion (0.4 ml) – Calcineurin Inhibitor for Chronic Dry Eye

Restasis 0.05% Ophthalmic Emulsion (0.4 ml) is a preservative-free topical immunomodulator containing cyclosporine, indicated to increase natural tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca (chronic dry eye disease). By inhibiting calcineurin-mediated T-cell activation, it restores ocular surface immune homeostasis to promote sustained, endogenous tear flow.

What Is Restasis 0.05% Ophthalmic Emulsion?

Restasis 0.05% is an ophthalmic emulsion supplied in single-use 0.4 ml preservative-free plastic vials. It contains cyclosporine, a cyclic polypeptide immunosuppressant that targets the underlying autoimmune inflammatory cycle responsible for chronic keratoconjunctivitis sicca (dry eye disease).

Unlike traditional artificial tears that merely provide transient symptomatic surface lubrication, Restasis is a disease-modifying topical therapy. It addresses chronic inflammatory damage within the lacrimal glands and conjunctival tissue, stimulating the patient’s own ocular tissues to resume endogenous aqueous tear production.

Restasis is formulated for long-term daily management. Because it acts at the level of cellular immune modulation, therapeutic improvements typically build gradually, with meaningful increases in tear volume observable over several weeks to months of continuous compliance.
([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a00e5ba6-df27-4a00-bebe-8dfda8537b01))

How Does Restasis 0.05% Work?

In chronic dry eye syndrome, activated CD4+ T-lymphocytes infiltrate the lacrimal glands and ocular surface, releasing pro-inflammatory cytokines that disrupt neural signaling and suppress aqueous tear production:

• Cyclophilin Binding: Intracellularly, cyclosporine binds to its cytoplasmic receptor protein, cyclophilin, to form an active immunosuppressive complex.
• Calcineurin Phosphatase Inhibition: This drug-protein complex binds and inhibits calcineurin, a calcium/calmodulin-dependent phosphatase essential for dephosphorylating the Nuclear Factor of Activated T-cells (NF-AT).
• Suppression of Cytokine Transcription: By preventing NF-AT translocation into the nucleus, cyclosporine halts the transcription and secretion of pro-inflammatory cytokines—chiefly interleukin-2 (IL-2), interferon-gamma (IFN-γ), and tumor necrosis factor-alpha (TNF-α).
• Lacrimal Gland Functional Recovery: Halting T-cell mediated ocular surface inflammation reduces apoptosis in conjunctival goblet cells and restores neurosecretory signaling, allowing the lacrimal functional unit to produce natural tears.

Because cyclosporine acts as an immunomodulator rather than a general vasoconstrictor or broad corticosteroid, it suppresses targeted inflammatory pathways without increasing intraocular pressure or inducing cataract formation.

What Is Restasis 0.05% Used For?

Restasis is clinically approved for increasing tear production in specific inflammatory ocular conditions:

• Chronic Keratoconjunctivitis Sicca (Dry Eye Disease): Patients whose natural tear secretion is diminished due to underlying ocular surface inflammation.
• Sjögren’s Syndrome-Associated Dry Eye: Long-term management of autoimmune lacrimal gland hypofunction under ophthalmic supervision.
• Corneal Epithelial Erosion Prevention: Preservation of corneal surface integrity in chronic severe dry eye unresponsive to tear substitutes alone.
• Conjunctival Goblet Cell Recovery: Promotion of mucin-layer stability by restoring conjunctival epithelial goblet cell density.

Increased tear production is not typically observed in patients currently using topical anti-inflammatory drugs (such as corticosteroids) or in individuals with mechanical lacrimal gland obstruction or punctal plug closure.
([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a00e5ba6-df27-4a00-bebe-8dfda8537b01))

Related Ocular Surface Therapy

While Restasis targets chronic autoimmune tear-deficiency and lacrimal inflammation, allergic ocular itching, redness, and swelling require dual-action antihistamine and mast-cell stabilizing agents. Explore our clinical review of Pataday:

Pataday Eye Drop (Olopatadine Hydrochloride)

Restasis 0.05% Dosage and Administration Guidelines

Aseptic technique and proper preparation ensure correct delivery of the emulsion:

• Standard Dosing: Instill 1 drop into each affected eye twice daily, approximately 12 hours apart.
• Emulsion Preparation: Invert the single-use vial several times prior to opening to obtain a uniform, white, opaque emulsion.
• Immediate Single-Use Application: Open the vial by twisting off the tab. Instill the drop immediately into the conjunctival sac. Discard the vial and any remaining contents immediately after application; single-use vials contain no antimicrobial preservatives.
• Spacing with Artificial Tears: Restasis can be used concomitantly with lubricating artificial tears, provided administrations are separated by at least 15 minutes.

To preserve sterile conditions, do not allow the vial tip to touch the eye surface, fingers, or surrounding skin.
([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a00e5ba6-df27-4a00-bebe-8dfda8537b01))

Restasis 0.05% vs Pataday Eye Drops (Olopatadine)

Comparing a chronic immunomodulatory emulsion with an acute antiallergic agent clarifies their distinct clinical mechanisms and treatment goals:

Restasis is indicated for ongoing immune-mediated tear deficiency, whereas Pataday provides fast, targeted relief for allergen-driven itching and histamine flares.

Who Should Not Use Restasis 0.05%?

Restasis is contraindicated or requires caution in patients with the following conditions:

• Known hypersensitivity or allergic reaction to cyclosporine or any excipients in the emulsion (castor oil, polysorbate 80, carbomer copolymer)
• Active ocular infections (viral, bacterial, or fungal keratitis or conjunctivitis); local immunomodulation may compromise host anti-infective clearance
• Children under 16 years of age (safety and efficacy have not been established in pediatric keratoconjunctivitis sicca)
• Use while wearing contact lenses during active ocular surface inflammation
• Pregnancy and nursing (use only if explicitly determined essential by an obstetrician and ophthalmologist)

Careful ophthalmic evaluation is recommended for patients with a history of herpes simplex keratitis prior to starting calcineurin inhibitor drops.
([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a00e5ba6-df27-4a00-bebe-8dfda8537b01))

Possible Side Effects of Restasis

Systemic absorption of cyclosporine following topical ocular administration is negligible, and adverse events are largely localized to the ocular surface:

• Ocular Burning & Stinging: The most common adverse effect (reported in ~17% of patients), typically occurring immediately after drop instillation and subsiding as the ocular surface heals over weeks.
• Conjunctival Hyperemia: Mild transient redness or vascular injection of the sclera.
• Epiphora & Ocular Discharge: Temporary reflex tearing or sticky ocular discharge.
• Visual Effects: Transient blurring of vision immediately following administration due to the thick emulsion vehicle.
• Foreign Body Sensation: Grittiness, ocular pain, pruritus, or stinging.

If severe, persistent eye pain, worsening corneal erosion, or signs of ocular infection emerge, contact an eye specialist immediately.
([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a00e5ba6-df27-4a00-bebe-8dfda8537b01))

Drug Interactions and Co-Administration Guidelines

Blood concentrations of cyclosporine following topical administration of Restasis remain below the limit of clinical assay quantification (< 0.1 ng/mL), eliminating systemic cytochrome P450 interactions:

Separation from Artificial Tears: If non-medicated artificial tears or lubricating gels are used, separate instillations by at least 15 minutes to prevent the tear substitute from diluting or washing away the cyclosporine emulsion.

Topical Ophthalmic Steroids: Concomitant use with topical corticosteroids may be used temporarily as a bridge to reduce early stinging or acute inflammation, but long-term combination requires careful monitoring of intraocular pressure.
([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a00e5ba6-df27-4a00-bebe-8dfda8537b01))

Preservative-Free Vial Handling & Storage

Restasis 0.4 ml unit-dose vials are completely preservative-free, avoiding benzalkonium chloride toxicity in already compromised dry eyes:

Each vial contains enough emulsion to dose both eyes once. Once opened, the vial must be discarded immediately after use, even if liquid remains. Attempting to save open vials for subsequent doses exposes the solution to bacterial and fungal contamination. Store unopened vials in their original foil pouch at controlled room temperature ($15^\circ\text{C to }25^\circ\text{C}$).

Treatment Timeline & Clinical Expectations

Because Restasis works through immunomodulation of the lacrimal functional unit, clinical improvements follow a gradual trajectory:

Weeks 1–4 (Initial Phase): Patients may experience transient burning or stinging upon instillation. Tear production is typically unchanged during this early phase; concurrent artificial tears help maintain surface comfort.

Weeks 6–12 (Early Objective Response): Ocular surface inflammation declines, conjunctival staining scores improve, and early increases in natural tear volume can be measured via Schirmer testing.

Months 3–6 (Sustained Improvement): Peak therapeutic increases in natural tear production, goblet cell density restoration, and symptom relief are generally achieved with continuous, uninterrupted twice-daily therapy.
([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a00e5ba6-df27-4a00-bebe-8dfda8537b01))

Official Medical Reference

For complete official prescribing guidelines, clinical trial outcomes, pharmacokinetic parameters, and safety monographs on cyclosporine ophthalmic emulsion, refer to the FDA DailyMed reference:

DailyMed – Restasis (Cyclosporine Ophthalmic Emulsion) Prescribing Information

Frequently Asked Questions About Restasis 0.05%

Medical Disclaimer

This product overview is provided strictly for educational and informational purposes. Restasis 0.05% Ophthalmic Emulsion (cyclosporine) is a prescription ophthalmic medication that must only be initiated, dosed, and monitored under the care of a licensed ophthalmologist or optometrist. Individual therapeutic response, tolerance, and underlying ocular surface disease etiology require specialized clinical evaluation. This document does not replace professional medical evaluation, clinical diagnosis, or personalized ophthalmic management.